No data

No data

2025

2022

2019

2018

2017

2016

2015

2014

2013

2012

2011

2009

2008

2007

2001

1995

1993

2025
2022
2019
2018
2017
2016
2015
2014
2013
2012
2011
2009
2008
2007
2001
1995
1993

  • Jinhao Pharmaceutical’s nucleic acid detection kit for Chikungunya virus, its IgM/IgG antibody detection kit, and its antigen detection kit are supporting epidemic prevention and control efforts in Guangdong and other regions.

  • Kexin Bio’s autoimmune inflammatory myopathy antibody panel (IgG) assay kit has obtained medical device registration approval.

  • Kexin Bio’s autoimmune diabetes antibody profile assay kit has obtained medical device registration approval.

  • Jinhao Pharmaceutical is focusing on the development and innovation of applications for its Mycobacterium tuberculosis effector T-cell assay kit.

  • Defu Investment invests in Ke Xin Bio.

  • Ankang Inspection has obtained the CMA accreditation certificate.

  • Kexin Bio Completes the Investment and Acquisition of Ankang Testing

  • Guizhou Ankang Medical Laboratory Center Established

  • Jinhao Pharmaceutical’s HIV‑1 incident‑infection ELISA kit has been approved for market launch following evaluation by both the U.S. CDC and the Chinese CDC.

  • Kexin Bio Completes the Investment and Acquisition of Ruifu Medical

  • Jinhao Pharmaceutical has successfully developed an RNA detection kit for the H7N9 subtype of avian influenza virus.

  • Jinhao Pharmaceutical has obtained ISO/IEC 17025:2005 laboratory accreditation.

  • Shanghai Kexin Biotechnology Co., Ltd. was established.

  • Jinhao Pharmaceutical’s biosafety reagent services support Olympic security.

  • Beijing Jinhao Pharmaceutical Co., Ltd. was established.